PR Newswire
LONDON, March 23, 2026
LONDON, March 23, 2026 /PRNewswire/ — The global animal drug compounding market is growing steadily, expected to be valued at around US$1.5 in 2026 and projected to reach US$2.3 by 2033, with a CAGR of 6.6% in the coming years. This expansion is driven by rising pet ownership, increasing veterinary healthcare expenditure, and the growing need for personalized medication formulations. Compounded animal drugs allow flexibility in dosage, flavoring, and delivery methods, making treatments more effective and easier to administer. Market dynamics reflect a shift toward individualized veterinary care, supported by expanding compounding pharmacy networks and technological advancements in formulation techniques.
https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
Key Highlights
- The global animal drug compounding market is projected to reach US$ 2.3 Billion by 2033, growing steadily with strong demand for personalized veterinary treatments.
- North America leads with a 42% market share, driven by high pet ownership, advanced veterinary infrastructure, and strong regulatory support.
- Asia Pacific emerges as the fastest-growing region, supported by rising pet adoption, urbanization, and expanding veterinary healthcare services.
- By product type, CNS agents dominate with around 33% of market revenue, reflecting high demand for neurological and behavioral treatments in companion animals.
- Anti-infective agents are the fastest-growing segment, fueled by increasing focus on infection control and customized antimicrobial therapies.
- Rising prevalence of chronic diseases in pets and growing animal healthcare expenditure continue to strengthen long-term market demand.
PDF Sample Inside: https://www.persistencemarketresearch.com/samples/12871
Rising Pet Ownership and Humanization Trends
The rapid increase in companion animal ownership worldwide is a major driver of the animal drug compounding market. Pets are increasingly treated as family members, leading to higher spending on advanced healthcare and customized treatments. This shift fuels demand for compounded medications that address specific conditions, allergies, and dosage requirements not met by standard drugs. Globally, pet healthcare spending has surged significantly, with rising adoption rates and growing awareness of animal wellness contributing to sustained demand. In developed regions, households allocate substantial budgets toward veterinary services, while emerging economies are witnessing increased adoption of pets in urban areas.
Compounded medications improve compliance by offering flavored formulations, liquid suspensions, and transdermal gels, especially for animals that resist conventional pills. This enhances treatment adherence and therapeutic outcomes, particularly in chronic conditions. In urban markets across Asia Pacific and Latin America, increasing disposable income and awareness of pet care are accelerating adoption of personalized veterinary medicines. This trend ensures long-term growth opportunities for compounding pharmacies and veterinary service providers.
Growing Prevalence of Chronic Diseases in Animals
The rising incidence of chronic diseases among animals is another key factor driving market growth. Conditions such as diabetes, arthritis, cardiovascular diseases, and cancer are becoming more common in pets due to longer lifespans and improved diagnostics. Studies indicate that around 25% of dogs suffer from arthritis, while diabetes affects a notable percentage of companion animals, requiring long-term medication management. These conditions often demand precise dosing and tailored drug combinations, which standard pharmaceuticals cannot always provide.
Compounded drugs enable veterinarians to customize therapies based on species, size, and medical history. For example, cats that cannot tolerate oral tablets can receive transdermal gels, while dogs may benefit from flavored chewable medications. The livestock segment also contributes significantly, as farmers seek specialized formulations to manage herd health, prevent disease outbreaks, and comply with regulatory standards on drug residues. This broad application across animal types strengthens market demand globally.
Advancements in Formulation Technologies and Delivery Methods
Technological innovation plays a crucial role in shaping the animal drug compounding market. Advances in pharmaceutical compounding techniques have enabled the development of diverse dosage forms, including flavored suspensions, topical creams, sterile injectables, and extended-release formulations. Modern compounding facilities use precision equipment and sterile environments to ensure quality, consistency, and safety in drug preparation. Innovations such as flavor masking and non-invasive delivery systems improve medication acceptance among animals, reducing stress during administration.
The integration of telemedicine and e-commerce platforms is further transforming the market. Veterinary clinics now collaborate with compounding pharmacies to deliver customized prescriptions directly to pet owners, enhancing convenience and accessibility. These advancements align with the broader trend of personalized medicine, mirroring developments in human healthcare and reinforcing the importance of tailored treatment approaches in veterinary practice.
Request Customization:
https://www.persistencemarketresearch.com/request-customization/12871
Key Highlight: $3.5 Billion Strategic Merger between Cencora and Covetrus in 2026
- A major development in 2026 was the announcement that Cencora will merge its animal health subsidiary, MWI Animal Health, with Covetrus in a deal valued at $3.5 billion. The transaction is aimed at forming a combined animal health distribution and technology platform, strengthening capabilities across the veterinary supply chain.
- Under the agreement, Cencora will receive $1.25 billion in cash, $800 million in preferred equity, and $1.45 billion in common equity, while retaining a 34.3% non-controlling stake in the merged entity. The move aligns with Cencora’s strategy to divest non-core operations and sharpen focus on its core drug distribution business.
- The merger combines MWI’s animal health distribution network with Covetrus’ technology and service capabilities, creating a more comprehensive platform to support veterinary practices and improve access to animal healthcare solutions.
This development signals a broader consolidation trend in the animal health and compounding ecosystem, where companies are integrating distribution, technology, and veterinary services. It is expected to enhance efficiency, expand market reach, and support future delivery of animal health products, including compounded medications, through more integrated supply chains.
Segmentation Insights: CNS Agents Lead While Anti-Infectives Accelerate Rapid Growth
CNS (Central Nervous System) agents dominate the global animal drug compounding market, accounting for around 33% of market revenue, driven by strong demand for customized treatments addressing neurological and behavioral conditions such as anxiety, seizures, and chronic pain in companion animals. Their leadership stems from the need for tailored dosages, improved palatability, and species-specific formulations that standard drugs often fail to provide. Meanwhile, anti-infective agents represent the fastest-growing segment, expanding at a notable CAGR through 2033 due to rising concerns around infection control, antimicrobial resistance, and the need for targeted therapies in both companion and livestock animals. A key development supporting this growth is the increasing adoption of advanced compounding technologies that enable precise formulation of antimicrobial drugs, enhancing treatment efficacy and compliance while addressing gaps in commercially available veterinary medications.
Regional Insights: North America Dominates While Asia Pacific Emerges as the Fastest-Growing Market Hub
North America leads the global animal drug compounding market, accounting for an estimated 42% share, supported by high pet ownership levels and a well-established veterinary healthcare ecosystem. Over 70% of U.S. households owned pets as of 2023, while Canada reported around 60% ownership in 2022, creating consistent demand for customized veterinary medications. The region benefits from a strong regulatory framework, including FDA guidelines such as GFI #256, along with a dense network of compounding pharmacies catering to aging pets and chronic conditions. Europe holds a significant share and is projected to grow at a CAGR of around 7.9% from 2026 to 2033, driven by increasing expenditure on companion animal healthcare and demand for personalized treatments across countries such as Germany, France, and the UK. Asia Pacific represents the fastest-growing regional market, registering a comparatively higher CAGR through 2033, fueled by rising urbanization, expanding pet adoption, and improving veterinary infrastructure across China, India, Japan, and Australia. Growing awareness of advanced animal healthcare, coupled with increasing livestock productivity requirements, continues to accelerate demand for compounded veterinary drugs across the region.
Market Segmentation
By Product
- CNS Agents
- Anti-Infective Agents
- Hormones and Substitutes
- Anti-inflammatory Agents
- Others
By Animal
- Companion
- Cats
- Dogs
- Others
- Livestock
By Formulation
- Oral
- Injectable
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- The Middle East and Africa
View Full Report: https://www.persistencemarketresearch.com/checkout/12871
Key Players and Business Strategies
Leading players include Wedgewood Pharmacy, Diamondback Drugs, MEDISCA, Zoetis Inc., Elanco, and Covetrus.
- Wedgewood Pharmacy focuses on expanding its compounding capabilities and veterinary partnerships to strengthen market presence.
- Zoetis invests in advanced technologies and AI-driven formulations to enhance product development efficiency.
- Elanco is expanding production capacity to meet rising demand in emerging markets, particularly in Latin America.
- MEDISCA collaborates with veterinary clinics to improve access to customized drug solutions and increase market penetration.
- Covetrus leverages its distribution network to provide integrated veterinary healthcare solutions.
Strategies across the market emphasize personalization, technological innovation, partnerships, and expansion of compounding infrastructure. Companies are also focusing on regulatory compliance and quality assurance to maintain competitive advantage in this highly specialized segment.
Get More
Animal Health Market Reports
:
U.S. Animal Drug Compounding Market by Product (CNS Agents, Anti-Infective Agents, Hormones and Substitutes, Anti-inflammatory Agents, Others), Animal (Companion, Livestock), Formulation Oral, Injectable, OthersFormulation (Oral, Injectable, Others), and Regional Analysis from 2025 – 2032
Animal Health Active Pharmaceutical Ingredients Market by Animal Type (Companion Animals, Production Animals), by API Type (Antiparasitics, Anti-infectives, NSAIDs & Anesthetics, Others), by Regional Analysis, from 2026 – 2033
Compounding Pharmacies Market by Type (Oral Medication, Topical Medications, Mouthwashes, Suppositories) by Application (Medication for Adults, Medication for Veterinary, Medication for Children, Medication for Geriatric) by Therapeutic Area, by Sales Channel, and by Region
North America Vet Compounding Pharmacies Market by Product Type (CNS Agents, Anti-Infective Agents, Hormones and Substitutes, Anti-inflammatory Agents, Others), Animal Type, Formulation, and Regional Analysis from 2025 – 2032
Animal Healthcare Market by Drugs (Anti-Infective Agents, Anti-Inflammatory & Analgesic Agents, Parasiticides, Vaccines, Hormones & Substitutes, Nutritional Products, and Others), by Animals (Companion Animals, Farm Animals), by Route of Administration (Oral, Parenteral, Topical, and Others), by Distribution Channel, sand Regional Analysis from 2025 – 2032
Animal Protein Ingredients Market, Global Industry Trend Analysis 2012 to 2017 and Forecast 2017 – 2025
Veterinary Medicine Market by Animal Type (Production Animals, Companion Animals), Product Type (Biologics, Pharmaceuticals), Route of Administration (Oral, Injectable), Distribution Channel, and Regional Analysis for 2025 – 2032
Flavoured Veterinary Medications Market by Product Type (Tablets, Liquids, Chews, Powders), Animal Type (Companion Animals, Livestock Animals), Distribution Channel (Veterinary Clinics, Pharmacies, Online Stores, Others), and Regional Analysis for 2025 – 2032
OTC Pet Medication Market by Product Type (Fleas & Ticks, Pain Relief & Arthritis, Dewormers), by Pet Type (Dogs, Cats, Birds, Fish & Reptiles, Small Pets), by Medicine Form (Chewable & Tablets, Capsules & Ointment, Sprays), by Sales Channel and Regional Analysis
Animal Wound Care Market by Product (Surgical Wound Care, Traditional Wound Care, Advanced Wound Care), by Animal Type (Companion Animal, Livestock Animal), by End User (Veterinary Hospitals, Veterinary Clinics, Home Care), by Regional Analysis, from 2026 to 2033
About
Persistence Market Research:
At Persistence Market Research, we are pioneers in Market Research and Consulting, bringing you the most dynamic insights into market trends, consumer behaviours, and competitive intelligence! For over a decade, we’ve been at the forefront of delivering game-changing analytics and research that drive businesses toward growth.
Our extensive market report database is a go-to resource for Fortune 500 companies, savvy business investors, media and entertainment channels, and academic institutions, empowering them to navigate the global and regional business landscape with confidence. With thousands of statistics and in-depth analyses covering over 20 diverse industries across 25 major countries, we provide the insights you need to succeed in today’s competitive environment.
Contact
Ritika KhandelwalPersistence Market ResearchSecond Floor, 150 Fleet Street, London, EC4A 2DQ+44 203-837-5656United KingdomUSA Phone – +1 646-878-6329Email: [email protected]
Logo: https://mma.prnewswire.com/media/2876873/Persistence_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/animal-drug-compounding-market-to-reach-us-2-3-billion-by-2033–expands-amid-rising-pet-healthcare-demand-and-personalized-veterinary-medicine—persistence-market-research-302722040.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…